HeartFlow, Inc., a global leader in non-invasive AI solutions for heart care, recently shared seven-year data demonstrating that its AI-enabled Fractional Flow Reserve Computed Tomography (FFRCT) and Plaque Analysis support the long-term assessment of coronary artery disease (CAD) risk in clinically stable, symptomatic patients. The findings, presented at the 36th annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C., indicate that HeartFlow’s platform offers clinicians valuable insights to help predict and manage adverse events, such as myocardial infarctions, in patients with stable chest pain.

The ADVANCE-DK data, derived from the broader ADVANCE Registry, examined the impact of a coronary computed tomography angiography (CCTA) and FFRCT diagnostic pathway on clinical decision-making, downstream invasive coronary angiography (ICA), revascularisation, and major adverse cardiovascular events (MACE) in real-world settings. This subset of the study evaluated three groups: patients with normal FFRCT, those with complete revascularisation (CR), and those with incomplete revascularisation (IR).

Results over a seven-year follow-up show that revascularisation completeness strongly predicts clinical outcomes. Patients with incomplete revascularisation, as assessed by FFRCT, displayed a notably higher long-term risk of adverse events compared to those who had complete revascularisation or normal FFRCT (16.2% for IR versus 7.8% for CR and 5.7% for normal FFRCT). Combining plaque quantification and lesion-specific physiology through FFRCT provided a more reliable indicator of adverse events over the seven-year period, outperforming traditional baseline risk assessment and CCTA alone (AUC 0.73 vs 0.63).

A separate study on patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) further validated FFRCT’s role in identifying hemodynamically significant lesions. The study concluded that CCTA with or without FFRCT could have avoided 54% to 64% of unnecessary invasive tests for high-risk patients. FFRCT outperformed CCTA alone in pinpointing lesions likely to benefit from revascularisation, significantly enhancing the avoidance of unnecessary ICA (AUC 0.84 versus 0.65).

These findings highlight HeartFlow’s ability to support the early identification of CAD-related risks beyond the immediate. By offering lesion-specific assessments, HeartFlow’s FFRCT solution is shown to help clinicians avoid unnecessary invasive procedures while providing actionable insights that can improve patient outcomes. HeartFlow’s technology is currently in use across more than 1,300 institutions worldwide, strengthening its impact and reach in the fight against heart disease.
 

Source: heartflow.com

Report Abuse